biostudies-literatureSchouten PCLife Sciences Center Amsterdam (LSCA)Roche Life ScienceCancer Research UKMedical Research CouncilNational Institute for Health Research (NIHR)FP7 Collaborative Project “RATHER”1274-86https://www.ebi.ac.uk/biostudies/studies/S-EPMC5528812biostudies-literatureUnknown9(7)Breast cancers with BRCA1 germline mutation have a characteristic DNA copy number (CN) pattern. We developed a test that assigns CN profiles to be 'BRCA1-like' or 'non-BRCA1-like', which refers to resembling a BRCA1-mutated tumor or resembling a tumor without a BRCA1 mutation, respectively. Approximately one third of the BRCA1-like breast cancers have a BRCA1 mutation, one third has hypermethylation of the BRCA1 promoter and one third has an unknown reason for being BRCA1-like. This classification is indicative of patients' response to high dose alkylating and platinum containing chemotherapy regimens, which targets the inability of BRCA1 deficient cells to repair DNA double strand breaks. We investigated whether this classification can be reliably obtained with next generation sequencing Molecular oncologyRobust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.PMC552881216465MR/M008975/116942NF-SI-0611-10154Nederlof PMLips EHTutt ANKruizinga JKerkhoven RMKuilman TWatkins JASchouten PCRueda OMvan Dyk EHoogstraat MMirza HSeverson TMGrigoriadis ACaldas CCooke SAVens CLinn SCWessels LFNieuwland MPeeper DChin SFKrijgsman OVerhagen CVNatrajan RVelds AfalseRobust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.Breast cancers with BRCA1 germline mutation have a characteristic DNA copy number (CN) pattern. We developed a test that assigns CN profiles to be 'BRCA1-like' or 'non-BRCA1-like', which refers to resembling a BRCA1-mutated tumor or resembling a tumor without a BRCA1 mutation, respectively. Approximately one third of the BRCA1-like breast cancers have a BRCA1 mutation, one third has hypermethylation of the BRCA1 promoter and one third has an unknown reason for being BRCA1-like. This classification is indicative of patients' response to high dose alkylating and platinum containing chemotherapy regimens, which targets the inability of BRCA1 deficient cells to repair DNA double strand breaks. We investigated whether this classification can be reliably obtained with next generation sequencing 2015-01-01T00:00:00Z2015 Aug2026-05-05T20:48:08.355Z2019-03-27T02:51:44ZS-EPMC55288122582512010.1016/j.molonc.2015.03.002